PROTEUS S.A.

Proteus is devoted exclusively to research, characterization, collection, purification and packaging of neosaxitoxin. It complies with "cGMP's for Phase 1 Investigational drugs" of the U.S. FDA (conditioning Q2-2010). A micro algae research-driven biotechnology company. To explore the full potential of the active principle obtained from a specific micro-algae, improving patients’ quality of life by developing a variety of products and applications complying with national and international standards to market them globally.